Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

40.16 -0.28 (-0.69%)
Streaming Delayed Price Updated: 1:09 PM EDT, Jul 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
Via Investor Brand Network
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:REGN),(NASDAQ:VRTX),(OTCQX:RHHBY),(NYSE:MRK) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?
The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide. 
Via Investor's Business Daily
Trump Vows To Cut 'The Best Deal' On Drug Prices. What To Expect.
President Donald Trump, ever the negotiator, is angling to lower drug prices through his Most Favored Nation policy. 
Via Investor's Business Daily
Topics Government
Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug?
Biogen is hoping to top its own spinal muscular atrophy treatment, Spinraza, with a next-generation version. 
Via Investor's Business Daily
Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside
Septerna gains Buy rating as HC Wainwright highlights undervaluation, strong pipeline, and key partnership with Novo Nordisk in metabolic diseases. 
Via Benzinga
Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars
Exelixis' STELLAR-303 trial shows zanzalintinib plus Tecentriq improved survival in colorectal cancer, with no new safety concerns reported. 
Via Benzinga
Exelixis Catapults 14% On Positive Results For Next-Gen Colon Cancer Drug
Shares surged Monday after the company said its next-generation cancer drug showed promise in a colon cancer study. 
Via Investor's Business Daily
Two Biotech Stocks Poised For Big Moves On Monday
Via Benzinga
Genentech’s Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma
From Genentech
Via Business Wire
MAIA’s New Agreement With Big Pharma Roche Turns Retail Investors Bullish As Stock Soars
The agreement aims to support future studies investigating the combination of MAIA’s Ateganosine and Roche’s checkpoint inhibitor, Atezolizumab, for safe and effective cancer treatments. 
Via Stocktwits
Roche Stock Slides After Failed Blood Cancer Trial With AbbVie, But Parkinson’s Therapy Progress Boosts Retail Mood
The Swiss pharma giant advanced its anti-alpha-synuclein antibody prasinezumab to the next stage based on promising Phase IIb data. 
Via Stocktwits
Genentech Provides Update on Phase III Verona Study
From Genentech
Via Business Wire
Sarepta Therapeutics Stock Plummets Over 40% On Second Fatal Case Linked To Its Gene Therapy
Sarepta suspends Elevidys use in non-ambulatory Duchenne patients after two liver failure deaths, triggering FDA review and clinical trial pause. 
Via Benzinga
Topics Death
Genentech to Advance Prasinezumab Into Phase III Development for Early-Stage Parkinson’s Disease
From Genentech
Via Business Wire
Eli Lilly's Obesity Drug Success Spurs Japanese Biotech's Anti-Muscle-Wasting Combo Therapy
Chugai plans to pair its muscle-preserving drug with Eli Lilly's orforglipron, addressing muscle loss in obesity care as the market expands rapidly. 
Via Benzinga
Jazz Pharma's Zepzelca Combo Shows Survival Edge In Lung Cancer Study
Jazz Pharma's Zepzelca plus Tecentriq significantly improved survival in a Phase 3 study for extensive-stage small-cell lung cancer patients. 
Via Benzinga
Genentech’s Tecentriq Combined with Lurbinectedin Shows Significant Survival Benefit in Extensive-Stage Small Cell Lung Cancer
From Genentech
Via Business Wire
How AstraZeneca Is Playing Its Cancer Cards To Become An $80 Billion Pharma
Three new cancer drugs could help make a dent in the company's ambitious plans for 2030. 
Via Investor's Business Daily
New Data Show Genentech’s Itovebi Significantly Extended Survival in a Certain Type of HR-positive Advanced Breast Cancer
From Genentech
Via Business Wire
Roche's Multiple Sclerosis Drug Shows Low Disease Activity Over Two Years
Roche shares new data showing its MS drug fenebrutinib maintained low relapse rates and no disability progression in patients over 96 weeks. 
Via Benzinga
Genentech’s Fenebrutinib Maintains Near-Complete Suppression of Disease Activity and Disability Progression for up to Two Years in People With Relapsing Multiple Sclerosis
From Genentech
Via Business Wire
Roche Gets Positive Opinion For Approval Of Cancer Therapy In EU: Retail Yet To React
The company said that the European Commission is expected to make a decision soon regarding the approval for Itovebi. 
Via Stocktwits
Topics Government
New Two-year Follow-up of Genentech’s Columvi Extends Overall Survival in Relapsed or Refractory Diffuse Large B-cell Lymphoma Patients
From Genentech
Via Business Wire
FDA Approves Genentech’s Susvimo for Diabetic Retinopathy
From Genentech
Via Business Wire
The Smartest Vanguard ETF to Buy With $500 Right Now
Via The Motley Fool
Topics ETFs
Genentech Provides Update on FDA Advisory Committee Meeting on Columvi Combination for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
From Genentech
Via Business Wire
Novo Nordisk Sheds 4% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price
Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition. 
Via Investor's Business Daily
Merck Data Shows Positive Outcomes For Ovarian Cancer Patients Treated With Keytruda
Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ovarian cancer, including patients with PD-L1–positive tumors. 
Via Benzinga
Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030
Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.